DSIP
Human ResearchDelta Sleep-Inducing Peptide
Delta Sleep-Inducing Peptide, discovered in 1974. Researched for improving sleep quality, particularly delta wave (deep) sleep and REM sleep.
Dose
10-25 mcg
Route
SubQ injection, Nasal spray
Cycle
Typically 1-2 weeks, followed by a break
Storage
Refrigerated at 2-8°C (36-46°F), protected from light
What is DSIP?
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide first isolated from the cerebral venous blood of rabbits in 1974. Its primary research focus centers on its role in sleep regulation, particularly its ability to increase delta wave activity during non-REM sleep and normalize sleep cycles. Research has also explored its potential involvement in stress reduction, pain modulation, and withdrawal symptoms from certain substances. The mechanisms of action are thought to involve interactions with NMDA receptors, modulation of alpha 1-adrenergic receptors, and participation in the MAPK pathway, ultimately influencing neuronal activity related to sleep onset and depth. DSIP is often administered subcutaneously or intranasally in research settings.
Key Benefits
- Improved deep sleep
- Better REM sleep
- Sleep cycle normalization
- Potential addiction withdrawal support
Mechanism of Action
- Interacts with NMDA receptors
- Modulates alpha 1-adrenergic receptors
- MAPK pathway involvement
- Increases delta brain wave activity
Best For
- Sleep optimization research
- Insomnia research
- Recovery
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
848.9 Da
Length
9
Type
Peptide
Amino acid sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE)
Tryptophan-Alanine-Glycine-Glycine-Aspartic Acid-Alanine-Serine-Glycine-Glutamic Acid
Pharmacokinetics
Half-life
0.5 h
Research indicates a short half-life, approximately 30 minutes, although metabolic pathways and active metabolites may extend its functional duration.
Research Indications
Improved Deep Sleep
Numerous studies indicate DSIP's capacity to significantly increase the duration and intensity of delta wave activity, characteristic of deep, restorative NREM sleep.
Better REM Sleep
Research suggests DSIP can contribute to the normalization of REM sleep architecture, potentially improving overall sleep efficiency.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Enhance deep sleep (delta wave activity) | 10-25 mcg | Once daily, before bed | Subcutaneous injection or intranasal spray |
| Normalize sleep architecture in disturbed sleep | 15-20 mcg | Once daily, 30-60 minutes pre-sleep | Subcutaneous injection |
| Support during addiction withdrawal | 20-30 mcg | Once daily, or split into two doses (e.g., morning and evening) depending on specific withdrawal symptoms | Subcutaneous injection |
| General sleep improvement and recovery | 10 mcg | Every other day, before bed, for maintenance after initial phase | Intranasal spray |
| Investigation of stress reduction | 10-25 mcg | Once daily, typically in the evening | Subcutaneous injection |
Administration before bedtime aims to align with natural sleep initiation processes.
Peptide Interactions
- Monitor Combination
CNS Depressants (e.g., benzodiazepines, alcohol)
Concurrent use may lead to enhanced sedative effects or respiratory depression; careful monitoring and dose adjustment are advised in research settings.
- Monitor Combination
Stimulants (e.g., caffeine, amphetamines)
Stimulants may counteract the sleep-promoting effects of DSIP, potentially reducing its efficacy in sleep research protocols.
- Monitor Combination
Opioid Agonists/Antagonists
Given DSIP's potential interaction with opioid systems, concurrent use of opioid medications requires careful consideration and monitoring for altered effects or efficacy.
- Monitor Combination
Antidepressants (e.g., SSRIs, TCAs)
Interaction potential is not well-established. Monitor for altered sleep patterns, mood, or unexpected side effects if used concurrently in research.
- Compatible
Melatonin
Both influence sleep; some research suggests they may complement each other in promoting healthy sleep, potentially through different pathways. No known adverse interactions.
How to Reconstitute
- 1Gather DSIP vial, bacteriostatic water for injection (BWFI), and sterile syringes.
- 2Remove the protective cap from the DSIP vial and wipe the rubber stopper with an alcohol swab.
- 3Draw the desired amount of BWFI into a sterile syringe. Common research concentrations suggest 1-2 mL per vial.
- 4Slowly inject the BWFI into the DSIP vial, aiming the stream against the side of the vial to minimize direct impact on the peptide powder.
- 5Gently swirl (do not shake) the vial until the powder is completely dissolved. This may take several minutes.
- 6Once dissolved, the solution should be clear and free of particulate matter. Store reconstituted solution as recommended.
Aseptically reconstitute lyophilized DSIP with bacteriostatic water for injection (BWFI).
What to Expect
- Weeks 1-2: Initial observations may include subjective improvements in sleep onset latency and sleep quality. Polysomnographic studies might show increased delta wave activity.
- Weeks 3-4: Consistent administration may lead to more pronounced and stable improvements in sleep architecture, including a potential increase in REM sleep percentage.
- Weeks 5-6: Some research suggests sustained benefits in sleep cycle normalization. For protocols exploring addiction withdrawal, subjective symptom reduction might be reported.
- Beyond 6 weeks: Continued research cycles might explore long-term effects or dose tapering strategies, often with breaks between cycles to assess endogenous sleep regulation.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Morning grogginess | Uncommon | Mild |
| Vivid dreams | Uncommon | Mild |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.